Advertisement

Drugs & Therapy Perspectives

, Volume 34, Issue 10, pp 477–477 | Cite as

First reports of adverse drug reactions

Drug Reactions and Interactions
Table 1 contains an overview of first published case reports of adverse drug reactions identified in the international literature in recent weeks by Reactions Weekly, the Adis drug safety newsletter. Reactions Weekly provides summaries of adverse drug reaction news sourced from journals, scientific meetings, media releases, regulatory agency websites, and bulletins from the National Centers that participate in the WHO International Drug Monitoring Programme.
Table 1

First published reports of adverse drug reactions recently identified by Reactions Weekly

Drug and adverse reaction

References

Infigratinib: hypoglycaemic episodes

Tella SH, Pablo FV, Sedmak C, et al. Effect of BGJ398 on insulin sensitivity in a patient with tumor-induced osteomalacia [abstract no. SAT-150]. Endocr Rev 2018;39(2 Suppl). https://www.endocrine.org/meetings/endo-annual-meetings/abstract-details?ID=5882

Lutetium-(177lu)-oxodotreotide: acute pancreatitis (serious)

Karfis I, Marin G, MacHiels G, et al. Acute pancreatitis following peptide receptor radionuclide therapy: an unusual adverse event. Clin Nucl Med. 2018;43(7):e232–3.  https://doi.org/10.1097/rlu.0000000000002118

Memantine: manic episode

Duan J, Lao C, Chen J, et al. Memantine induces manic episode in a 73-year-old patient with vascular neurocognitive disorder: a case report. Neuropsychiatr Dis Treat. 2018;14:1395–8.  https://doi.org/10.2147/ndt.s160832

Methylprednisolone: Takotsubo cardiomyopathy (serious)

Candilio L, Moon T, Sado D, et al. Iatrogenic corticosteroids induced Takotsubo cardiomyopathy. Cardiovasc Revasc Med. 2018;19(4):471–3.  https://doi.org/10.1016/j.carrev.2017.09.013

Nepafenac: allergic urticaria

Yasar E, Kara DO, Yildirim N. A case of allergic urticaria after ophthalmic nepafenac use. Turk J Ophthalmol. 2018;48(3):146–9.  https://doi.org/10.4274/tjo.78614

Osimertinib: toxic epidermal necrolysis (serious)

Wang J, Cheng XY, Lu Y, et al. A case report of toxic epidermal necrolysis associated with AZD-9291. Drug Des Dev Ther. 2018;12:2163–7.  https://doi.org/10.2147/dddt.s168248

Pirfenidone: cutaneous lupus erythematosus (serious)

Kelly AS, De la Harpe Golden P, D’Arcy C, et al. Drug-induced lupus erythematosus secondary to pirfenidone. Br J Dermatol. 2018;178(6):1437–8.  https://doi.org/10.1111/bjd.16246

Pirfenidone: drug induced hypersensitivity syndrome (serious)

Suda K, Kamiya K, Chiang B, et al. A rare case of drug-induced hypersensitivity syndrome by pirfenidone for idiopathic pulmonary fibrosis. Allergol Int. 2018;67(3):425–6.  https://doi.org/10.1016/j.alit.2018.02.010

An event is serious (US FDA MedWatch definition) when the patient outcome is death, life threatening, hospitalization, disability, congenital anomaly or requires intervention to prevent permanent impairment or damage

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations